ischemic

LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE

Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented at International Stroke ConferenceData Show…

3 hours ago

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

3 months ago